Nivolumab for NSCLC in Japanese Patients: Similar Benefits, but Beware of Pneumonitis

ESMO Open - United Kingdom
doi 10.1136/esmoopen-2016-000119
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

P2.04-10 Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

182P: Intracranial Response to Nivolumab in NSCLC Patients With Untreated or Progressing CNS Metastases

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Vinorelbine/Carboplatin vs Gemcitabine/Carboplatin in Advanced NSCLC Shows Similar Efficacy, but Different Impact of Toxicity

British Journal of Cancer
Cancer ResearchOncology
2007English

P023 Factors Associated With Administration of Subsequent Cytotoxic Chemotherapy After Nivolumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-20 Advanced NSCLC Treatment and Outcomes After Nivolumab

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated With Nivolumab

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Looking for the Best Immune-Checkpoint Inhibitor in Pre-Treated NSCLC Patients: An Indirect Comparison Between Nivolumab, Pembrolizumab and Atezolizumab

International Journal of Cancer
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy